Schedule lll: From Milestone to Main Event-From the May 1st Court Proceedings to the June 29th DEA Hearing

Written By Shannon Shae

Today is April 23, 2026. This morning, the cannabis industry reached its most significant milestone in over half a century. Acting Attorney General Todd Blanche signed the historic order officially moving state-licensed medical cannabis to Schedule III of the Controlled Substances Act.

For medical operators, this is the moment the crushing weight of Section 280E finally begins to lift, promising a future of tax relief and financial viability. However, while we celebrate this massive move forward, the industry has to recognize that we are currently on a high-velocity collision course. A coordinated legal blockade is moving to freeze this progress before the ink is even dry.

The 2026 Roadmap: The June Hearing and the May 1st

The next 90 days will determine the fate of every retail, cultivation, and manufacturing license in the country. We are facing two critical dates that will define the era:

1. The May 1st Court Battle

We hit a critical point in the industry next week. On May 1, 2026 parties are scheduled to appear in person before Judge Trevor McFadden in D.C.

Previously, Judge McFadden denied a Temporary Restraining Order (TRO) allowing the Medicare CBD Pilot to launch on April 1st. But the May 1st hearing is for a Preliminary Injunction. If the opposition wins this, it creates a legal precedent that could freeze the entire Schedule III rescheduling order before it fully takes effect. While the May 1st hearing technically only concerns the Medicare Pilot, it is widely viewed as a "test case" for the broader Schedule III rescheduling.

  • The Strategy: The legal arguments S.A.M is using against the CMS Pilot for medical use are the exact same arguments they plan to use to challenge today’s Schedule III order in court.

2. The June 29th Hearing

While medical cannabis moved to Schedule III today, the DOJ has set June 29, 2026, as the start date for an expedited DEA administrative hearing regarding full rescheduling. This is where the battle for adult-use cannabis leaving Schedule I will be fought.

The Adversaries: A Look at Arguments

The opposition has evolved. They are targeting the industry’s administrative foundations.

The "Administrative Shortcut": SAM’s War on Procedure

Smart Approaches to Marijuana (SAM), led by Kevin Sabet, is banking on the Administrative Procedure Act (APA), the federal rulebook. They argue that rescheduling is a political shortcut rather than a scientific consensus, claiming the DOJ skipped mandatory notice-and-comment periods to rush a tax break for "Big Weed."

The Counter-Point: The defense rests on a Two-Part Test revolution. The HHS and DOJ replaced the rigid Five-Part Test with a modern standards that recognize Accepted Medical Use based on widespread clinical support and a 252-page scientific review. This isn't a "rush job"; it's a correction of a 50-year-old error.

The "Guinea Pig" Narrative: The Pharmaceutical Blockade

MMJ International Holdings is attacking the product itself. They claim retail cannabis is unvalidated medicine and argue that allowing seniors to access cannabinoids without FDA clinical trials makes them "policy guinea pigs."

The Counter-Point: Proponents argue that the clinical trial has been happening for 28 years at the state level. Bringing cannabis into Schedule III protects seniors by moving products from a federal vacuum into a regulated system where doctors and pharmacists can finally provide oversight and track safety.

The Treaty Trap: The "GOP 48" and the International Wall

A coalition of nearly 50 federal lawmakers, the "GOP 48," argues that the 1961 Single Convention on Narcotic Drugs mandates cannabis stay in Schedule I or II. They claim the Attorney General’s order is "ultra vires" (beyond his power).

The Counter-Point: Legal experts argue for Sovereign Flexibility. Schedule III provides more than enough control to satisfy treaty obligations. Precedents in Canada and Uruguay show that sovereign nations can prioritize domestic public health without violating the spirit of international conventions.

Tactical Plan: From Passive Compliance to Active Defense

To ensure this success is permanent, every operator, from the grow room to the retail floor, must contribute to the fight.

1. Register for the June 29th Hearing

You have the right to be in the room. Every business or individual affected by this rule must file a written notice of intention to participate by May 24, 2026. Flood the record with factual evidence of state-level success. Your data on safety and testing is the "scientific record" that defeats the "unvalidated medicine" narrative.

Every "interested person" (any business or individual affected by the rule) can request to participate. You must file a written notice with the intention of participating by May 24, 2026.

  • How to Do It: Send a PDF attachment to nprm@dea.gov or mail it to the Drug Enforcement Administration in Springfield, VA. Word of Caution: This is an expedited legal proceeding. If you intend to file, ensure your notice follows the specific format required by 21 CFR 1316.48

The Bottom Line

The opposition wins when we are isolated and silent. We win when we are integrated and vocal. The May 1st hearing and the June 29th DEA proceedings are shaping our future. Between now and then, our job is to make it politically and socially impossible for any judge to say that our business is anything less than an essential part of the American fabric.

The fight for 2026 is here. Let’s finish it.

Sources and References:

1. The April 23rd Milestone

  • Source: U.S. Department of Justice (DOJ) / Office of the Attorney General.

  • The Fact: On the morning of April 23, 2026, Acting Attorney General Todd Blanche signed the order reclassifying state-licensed medical marijuana and FDA-approved marijuana products to Schedule III.

  • Key Detail: The order specifically distinguishes between "licensed medical" and "unlicensed bulk" marijuana, the latter of which remains in Schedule I pending the June hearing.

  • Reference: CBS News: Justice Department eases restrictions on some marijuana products (April 23, 2026)

2. The May 1st "Flashpoint" (SAM v. Kennedy)

  • Source: U.S. District Court for the District of Columbia, Docket No. 1:26-cv-01081.

  • The Fact: Judge Trevor McFadden scheduled an in-person hearing for May 1, 2026, at 2:00 PM to hear arguments for a Preliminary Injunction.

  • The Adversaries: The lawsuit was brought by Smart Approaches to Marijuana (SAM) and joined by MMJ International Holdings on April 13, 2026.

  • Reference: Civil Rights Litigation Clearinghouse: SAM v. Kennedy Case Summary

3. The June 29th "Main Event" (DEA Hearing)

4. The "MMJ International" & Pharmaceutical Argument

5. The "GOP 48" & International Treaty Trap

6. Legal Format for Participation (21 CFR 1316.48)

  • Source: Code of Federal Regulations (CFR), Title 21, Section 1316.48.

  • The Fact: This regulation dictates the exact format required for a "Notice of Appearance" in a DEA hearing. Failure to follow this format is grounds for the Administrative Law Judge to deny "party status" in the June 29th hearing.

  • Reference: Legal Information Institute: 21 CFR § 1316.48 - Notice of appearance

Shannon Shae
Next

The "Not So Smart" Approaches to Marijuana: Exposing S.A.M